by barry101 | Mar 22, 2024 | Press Releases
– Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML – Company to host conference call and webcast Monday, March 25th at 8:30 AM ET – Company to issue...
by barry101 | Mar 20, 2024 | Press Releases
In-depth discussion of stratification of Company’s 2nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provided for clinical development strategy for advancement of Annamycin into potential AML pivotal registration study...
by barry101 | Mar 19, 2024 | Press Releases
HOUSTON, March 19, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
by barry101 | Mar 12, 2024 | Press Releases
Live webcast fireside chat on Monday, March 18th at 9:00 AM PT HOUSTON, March 12, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat...
by barry101 | Jan 24, 2024 | Press Releases
– MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment – MB-106 preliminary results: Intent to Treat CR rate of 40% plus a CR/ CRi rate of 47% (N=15); Dosed Per Protocol CR rate of 46% plus a CR/CRi rate of 54% (N=13)...
